NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
Dana-Farber Cancer Institute
Mario Negri Institute for Pharmacological Research
Kidney Cancer Research Bureau
University Hospital, Antwerp